Effects of lower dose of imatinib to CML patients

被引：22

作者：

Horikoshi, A ^{[1
]}

Takei, K ^{[1
]}

Sawada, S ^{[1
]}

机构：

[1] Nihon Univ, Nerima Hikarigaoka Hosp, Nerima Ku, Tokyo 1790072, Japan

来源：

LEUKEMIA RESEARCH | 2003年 / 27卷 / 12期

关键词：

D O I：

10.1016/S0145-2126(03)00101-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1167 / 1167

页数：1

共 3 条

[1] High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry [J].

Bakhtiar, R ;

Lohne, J ;

Ramos, L ;

Khemani, L ;

Hayes, M ;

Tse, F .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 768 (02) :325-340

[2] Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].

Druker, BJ ;

Talpaz, M ;

Resta, DJ ;

Peng, B ;

Buchdunger, E ;

Ford, JM ;

Lydon, NB ;

Kantarjian, H ;

Capdeville, R ;

Ohno-Jones, S ;

Sawyers, CL .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037

[3] Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. [J].

Kantarjian, H ;

Sawyers, C ;

Hochhaus, A ;

Guilhot, F ;

Schiffer, C ;

Gambacorti-Passerini, C ;

Niederwieser, D ;

Resta, D ;

Capdeville, R ;

Zoellner, U ;

Talpaz, M ;

Druker, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (09) :645-652

← 1 →